Carotid Artery Plaque Progression: Proposal of a New Predictive Score and Role of Carotid Intima-Media Thickness.
HAD2S score
carotid intima-media thickness
carotid plaque progression
cerebrovascular disease
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
11 01 2022
11 01 2022
Historique:
received:
15
11
2021
revised:
05
01
2022
accepted:
08
01
2022
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
1
3
2022
Statut:
epublish
Résumé
We aimed to investigate if the carotid intima-media thickness (IMT) at baseline and the HAD We performed a retrospective analysis on real-life prospectively collected data from patients with any detectable carotid plaque at follow up. The plaque score, calculated at baseline (T0) and at a median follow up of 36.6 months (IQR 39.6-34.3) (T3), was defined as 0: no plaque or stenosis < 30%; 1: stenosis in the range 30-49%; 2: in the range 50-69%; 3: in the range 70-99% and 4: occlusion. Carotid IMT was measured at T0 and T3; HAD We included 340 patients with a mean age of 69.9 (9.1) years and 25.3% subjects had plaque progression. Individuals with progression had a median HAD Baseline IMT could be considered a predictor of progression. Patients with progression had an HAD
Sections du résumé
BACKGROUND
We aimed to investigate if the carotid intima-media thickness (IMT) at baseline and the HAD
METHODS
We performed a retrospective analysis on real-life prospectively collected data from patients with any detectable carotid plaque at follow up. The plaque score, calculated at baseline (T0) and at a median follow up of 36.6 months (IQR 39.6-34.3) (T3), was defined as 0: no plaque or stenosis < 30%; 1: stenosis in the range 30-49%; 2: in the range 50-69%; 3: in the range 70-99% and 4: occlusion. Carotid IMT was measured at T0 and T3; HAD
RESULTS
We included 340 patients with a mean age of 69.9 (9.1) years and 25.3% subjects had plaque progression. Individuals with progression had a median HAD
CONCLUSION
Baseline IMT could be considered a predictor of progression. Patients with progression had an HAD
Identifiants
pubmed: 35055580
pii: ijerph19020758
doi: 10.3390/ijerph19020758
pmc: PMC8776120
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Hypertens. 2015 Dec;33(12):2471-6
pubmed: 26378685
Stroke. 2003 Oct;34(10):2367-72
pubmed: 12958327
Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1622-9
pubmed: 10845881
Circulation. 2000 Jan 4;101(1):E16-22
pubmed: 10618318
Stroke. 2013 Mar;44(3):792-4
pubmed: 23287778
J Ultrasound Med. 2010 Dec;29(12):1759-68
pubmed: 21098848
Stroke. 2004 Sep;35(9):2150-4
pubmed: 15243147
Diabetes Care. 2003 Apr;26(4):1251-7
pubmed: 12663606
J Neurol. 2006 Mar;253(3):321-7
pubmed: 16208526
J Neuroimaging. 2014 Sep-Oct;24(5):473-8
pubmed: 25340183
Cerebrovasc Dis. 2012;34(4):290-6
pubmed: 23128470
Atherosclerosis. 2018 Feb;269:57-62
pubmed: 29274849
J Am Soc Nephrol. 2008 Apr;19(4):757-63
pubmed: 18184855
Stroke. 2012 Jul;43(7):1818-23
pubmed: 22550052
Atherosclerosis. 2005 Apr;179(2):325-31
pubmed: 15777549
Stroke. 2003 Oct;34(10):2374-9
pubmed: 12947155
J Atheroscler Thromb. 2016 Aug 1;23(8):940-9
pubmed: 26887219
Clin Neurol Neurosurg. 2009 Apr;111(3):246-50
pubmed: 19036498
Stroke. 2014 Nov;45(11):3257-62
pubmed: 25213342
N Engl J Med. 1999 Jan 7;340(1):14-22
pubmed: 9878640
Cerebrovasc Dis. 2007;23(1):75-80
pubmed: 17108679
Eur J Clin Invest. 2020 Apr;50(4):e13217
pubmed: 32112400
Atherosclerosis. 2010 Jun;210(2):452-7
pubmed: 20079904
Stroke. 2010 Oct;41(10):2375-7
pubmed: 20814002
J Cereb Blood Flow Metab. 2013 Apr;33(4):619-24
pubmed: 23361391